跳至主要内容
临床试验/NL-OMON41010
NL-OMON41010撤回4 期

Renal Sympathetic Denervation in patients with therapy-resistant Catecholamine Polymorphic Ventricular Tachycardia (CPVT) and Long QT Syndrome (LQTS) * RESIDENT Study - RESIDENT Study

Academisch Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
撤回
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Inclusion Criteria
  • 1. Subjects who have provided written informed consent;
  • 2. Subjects who are * 18 years of age;
  • 3. Subjects who in the last year have had at least 1 event related to therapy refractory CPVT or LQTS
  • 4. Subjects with a eGFR * 45 ml/min per 1.73m2;
  • 5. Subjects who are willing and able to comply with all study procedures. ;Anatomical Inclusion Criteria
  • 1. Subjects with or without an accessory renal artery who have a main renal artery diameter of * 3.5 mm and * 7.0 mm for each of their kidneys
  • 2. Subjects who have a main renal artery without significant stenosis (defined as < 30%)
  • 3. Subjects who have a renal artery length of * 15 mm.

排除标准

  • 1. Subjects who are contraindicated for intravascular contrast material;
  • 2. Subjects who are contraindicated for anticoagulation medications (heparin, aspirin, Angiomax, etc.), analgesic medications (morphine, fentanyl, etc.), anxiolytic medications (alprazolam, lorazepam, diazepam, etc.) or other medications required for an interventional procedure;
  • 3. Subjects with known bleeding or hyper-coagulation disorders;
  • 4. Subjects who have type 1 diabetes mellitus;
  • 5. Subjects who have experienced a myocardial infarction, unstable angina pectoris, uncompensated heart failure, or a cerebrovascular accident within six (6) months prior to the screening visit, or have widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques;
  • 6. Subjects who have planned percutaneous vascular or surgical intervention for any reason within the next six (6) months;
  • 7. Subjects who have hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous;
  • 8. Subjects who have any serious medical condition, which in the opinion of the investigator, may adversely affect patient safety or the efficacy of the procedure in the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders);
  • 9. Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to the procedure;
  • 10. Subjects who have a known, unresolved history of drug use or alcohol abuse/dependency;
  • 11. Subjects who are currently enrolled in any investigational study wherein patient participation has not been completed;
  • 12. Subjects who, for any reason, may not be able to understand or comply with instructions. ;Anatomical Exclusion Criteria
  • 1. Subjects with only one kidney;
  • 2. Subjects with prior renal denervation procedure;
  • 3. Subjects with prior intervention to right or left renal artery;
  • 4. Subjects with renal artery stenosis as defined by * 30% stenosis confirmed by angiography with two (2) orthogonal views with selective catheterization;
  • 5. Subjects with iliac stenosis requiring intervention at time of procedure and/or within the next six (6) months;
  • 6. Subjects with severe femoral, renal, iliac or aortic calcification that may cause a potential complication at the time of the procedure;
  • 7. Subjects in which the physician is unable to cannulate the renal artery;
  • 8. Subjects in which the physician is unable to access the femoral artery by percutaneous means.

研究者

相似试验